Norcantharidin enhances TIMP-2 anti-vasculogenic mimicry activity for human gallbladder cancers through downregulating MMP-2 and MT1-MMP

• Published in: International journal of oncology Vol. 46; no. 2; pp. 627 - 640
• Main Authors: ZHU, WEI, SUN, WEI, ZHANG, JING-TAO, LIU, ZHONG-YAN, LI, XIN-PING, FAN, YUE-ZU
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.02.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Angiogenesis; Animals; anti-vasculogenic mimicry therapy; Antimitotic agents; Antineoplastic agents; Apoptosis - drug effects; Biomedical research; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage; Cancer therapies; Cell Line, Tumor; Cell Proliferation - drug effects; Drug therapy; Ethics; Gallbladder; Gallbladder cancer; gallbladder neoplasm; Gallbladder Neoplasms - genetics; Gallbladder Neoplasms - pathology; Gene Expression Regulation, Neoplastic - drug effects; Health aspects; Human subjects; Humans; Immunoglobulins; International organizations; Kinases; matrix metalloproteinase; Matrix Metalloproteinase 14 - biosynthesis; Matrix Metalloproteinase 2 - biosynthesis; Medical prognosis; Medical records; Medical research; Melanoma; Mice; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - genetics; Neovascularization, Pathologic - pathology; norcantharidin; Physiological aspects; Prognosis; Proteases; Proteins; Studies; Survival analysis; Tissue Inhibitor of Metalloproteinase-2 - biosynthesis; Tumors; vasculogenic mimicry; Xenograft Model Antitumor Assays; China

Vasculogenic mimicry (VM) is a tumor microcirculation pattern in highly aggressive gallbladder cancers (GBCs). We recently reported the anti-VM activity of norcantharidin (NCTD) in highly aggressive GBC-SD cells and xenografts. In this study, we further investigated that NCTD enhanced tissue inhibit...